JBM  Vol.5 No.8 , August 2017
Evaluation of Adverse Events Following Immunization against Rotavirus Regardless of Recommended Age Restriction
Abstract: Introduction: Mild and moderate Adverse Events Following Immunization (AEFI) against Rotavirus has not received much attention when the vaccine is administered regardless of recommended age restriction. Objectives: To describe the behavior of mild and moderate AEFI in immunized subjects against Rotavirus, in who age restriction period had not been considered. Methods: A case-control study in which we included immunized patients with monovalent oral vaccine against rotavirus and divided them into two groups: 1) Infants who received RV1 vaccine without considering the recommended period, and 2) Infants who were vaccinated with the recommended schedule. Results: From the total doses, 143/1894 (7.5%) were administered outside the restriction period. The most frequent AEFIs with the first dose were purpura, polypnea, and rhinorrhea; For the second dose: purpura, bloody stools, irritability and rhinorrhea. Conclusions: This study shows the benefits from vaccination regardless of age restriction are more beneficial compared to the possible risks of AEFI.
Cite this paper: Reyna-Figueroa, J. , Bercholc-Urinowsky, I. , Cardoso-Yah, G. , Vazquez-Alvarado, R. , Ramos-López, D. , Campos-Romero, F. , Handelsman, C. and Limón-Rojas, A. (2017) Evaluation of Adverse Events Following Immunization against Rotavirus Regardless of Recommended Age Restriction. Journal of Biosciences and Medicines, 5, 78-82. doi: 10.4236/jbm.2017.58006.

[1]   Richardson, V., Hernandez, J., Quintanar, M., Esparza, M., Johnson, B. and Gomez, C. (2010) Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico. The New England Journal of Medicine, 362, 299-305.

[2]   Fernandes, E.G., Leshem, E., Patel, M., Flannery, B., Pellini, A.C., Veras, M.A. and Sato, H.K. (2016) Hospital-Based Surveillance of Intussusception among Infants. Journal de Pediatrics, 92, 181-187.

[3]   Black, S. (2015) The Costs and Effectiveness of Large Phase III Pre-Licensure Vaccine Clinical Trials. Expert Review of Vaccines, 14, 1543-1548.

[4]   Armah, G., Pringle, K., Enweronu-Laryea, C.C., Ansong, D., Mwenda, J.M., Diamenu, S.K., Narh, C., Lartey, B., Binka, F., Grytdal, S., Patel, M., Parashar, U. and Lopman, B. (2016) Impact and Effectiveness of Monovalent Rotavirus Vaccine against Severe Rotavirus Diarrhea in Ghana. Clinical Infectious Diseases, 62, S200-207.

[5]   WHO (2009) Rotavirus Vaccines: An Update. The Weekly Epidemiological Record, 84, 533-540.

[6]   Patel, M.M., Clark, A.D., Sanderson, C.F.B., Tate, J. and Parashar, U.D. (2012) Removing the Age Restrictions for Rotavirus Vaccination: A Benefit-Risk Modeling Analysis. PLOS Medicine, 9, e1001330.

[7]   Reyna, F.J., Vidal, R.P. and Richardson, L.C.V. (2011) Inmunización contra rotavirus con vacuna oral monovalente. Revista de Investigación Clínica, 63, 391-398.

[8]   Yen, C., Figueroa, J., Uribe, E., Carmen-Hernández, L., Tate, J., Parashar, U., et al. (2011) Monovalent Rotavirus Vaccine Provides Protection Against an Emerging Fully Heterotypic G9P [4] Rotavirus Strain in Mexico. The Journal of Infectious Diseases, 204, 783-786.

[9]   Ndeffo Mbah, M.L., Liu, J., Bauch, C.T., Tekel, Y.I., Medlock, J., et al. (2012) The Impact of Imitation on Vaccination Behavior in Social Contact Networks. PLOS Computational Biology, 8, e1002469.

[10]   Patel, M.M., Lopez-Collada, V.R., Bulhoes, M.M., De Oliveira, L.H., Bautista, M.A., et al. (2011) Intussusception Risk and Health Benefits of Rotavirus Vaccination in Mexico and Brazil. New England Journal of Medicine, 364, 2283-2292.

[11]   Raebel, M.A. and Ou, B.S. (1999) Rotavirus Disease and Its Prevention in Infants and Children. Pharmacotherapy, 19, 1279-1295.

[12]   Patel, M.M., Clark, A.D., Glass, R.I., Greenberg, H., Tate, J., et al. (2009) Broadening the Age Restriction for Initiating Rotavirus Vaccination in Regions with High Rotavirus Mortality: Benefits of Mortality Reduction versus Risk of Fatal Intussusception. Vaccine, 27, 2916-2922.